Lantern Pharma Inc. Q2 2026: Net income $(7.07M), EPS $(0.57) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Lantern Pharma Inc. reported a Q2 2026 net loss of $7.07M, or $0.57 per share, widening from the prior year's $4.33M loss. The company generated no revenue for the first half of 2026. Key developments include advancing clinical candidates LP-300, LP-184, and LP-284, launching Zeta.ai partnerships, and continuing ADC program collaborations. R&D spending decreased due to lower trial activity, while G&A costs rose.
Lantern Pharma Inc. reported results for the quarter ended June 30, 2026, posting a consolidated net loss of $(7.07M), or $(0.57) per share (basic and diluted), versus a net loss of $(4.33M), or $(0.40) per share, in the year‑ago quarter. The company reported no revenue for the six‑month periods ended June 30, 2026 or 2025.
Financial Highlights
- Net income: Consolidated net loss of $(7.07M) for Q2 2026 vs. net loss of $(4.33M) in Q2 2025 (approximately (63%) worse YoY).
- Diluted EPS: Loss per share, basic and diluted of $(0.57) for Q2 2026 vs. $(0.40) in Q2 2025.
- Revenue: No revenues recognized for the six‑month periods ended June 30, 2026 or 2025.
Business Highlights
- Clinical pipeline: Advanced three clinical-stage candidates — LP-300, LP-184 (Phase 1a completed) and LP-284 (Phase 1A ongoing).
- AI commercialization: Launched withZeta.ai and formed Open Medicine AI to commercialize a multi-agent co-scientist platform.
- Targeted trials: Continued use of RADR® A.I. to refine patient selection, including focusing LP-300 Harmonic™ on the EGFR L858R subgroup to improve trial efficiency.
- ADC and preclinical work: Continued ADC program development in collaboration with Bielefeld using a cryptophycin payload that has shown promising preclinical potency.
- Cost and operations: R&D spending declined year over year due to lower trial activity, while G&A investments increased in business development, investor relations and staffing.
Original SEC Filing: Lantern Pharma Inc. [ LTRN ] - 10-Q - Aug. 14, 2026